Gilbert L, Elwood L J, Merino M, Masood S, Barnes R, Steinberg S M, Lazarous D F, Pierce L, d'Angelo T, Moscow J A
Medicine Branch, National Cancer Institute, Bethesda, MD 20892.
J Clin Oncol. 1993 Jan;11(1):49-58. doi: 10.1200/JCO.1993.11.1.49.
Previous studies have indicated that RNA levels for pi-class glutathione S-transferase (GST pi), a phase II, drug-metabolizing enzyme, were inversely related to estrogen receptor (ER) and progesterone receptor (PR) levels in human breast tumors. Because GST pi also is expressed in normal breast epithelium, an immunohistochemical assay that uses affinity-purified polyclonal antibodies to GST pi was developed to examine the possible relationship between GST pi expression in breast cancer cells and hormone receptor expression, as well as prognosis, in patients with primary breast cancer.
A strong inverse correlation between GST pi expression and ER (two-sided P [P2] = .002) and PR status (P2 = .023) was found in our study of 189 patients with primary breast cancer. GST pi expression was not related to tumor size, nodal metastasis, nuclear grade, histology, or age of the patient. In node-negative breast cancer (n = 72), increased GST pi expression was associated with decreased disease-free survival (DFS) and overall survival (OS). When GST pi expression was divided into categories of negative (no GST pi-positive tumor cells), intermediate (1% to 70% GST pi-positive tumor cells), and high (> 70% GST pi-positive tumor cells), the relative risk of tumor recurrence in patients with node-negative breast cancer was increased 3.39-fold for each successive category of expression (P2 = .0045; 95% confidence interval, 1.46 to 7.87) and the relative risk of death was increased 4.49-fold for each successive category (P2 = .0003; 95% confidence interval, 2.02 to 10.42). The actuarial 5-year OS was 100%, 79%, and 51%, and the DFS was 94%, 77%, and 44%, for the negative, intermediate, and high tumor groups, respectively. Among the factors studied in multivariate analysis (ER status, PR status, nuclear grade, and tumor size), GST pi expression was the factor that most accurately predicted shorter DFS and OS in node-negative patients.
GST pi expression is inversely related to hormone receptor status in breast cancer. This pilot study also suggests that increased GST pi expression may be an important predictor of early recurrence and death in node-negative breast cancer patients that merits additional investigation.
既往研究表明,Ⅱ相药物代谢酶π类谷胱甘肽S-转移酶(GSTπ)的RNA水平与人类乳腺肿瘤中的雌激素受体(ER)和孕激素受体(PR)水平呈负相关。由于GSTπ也在正常乳腺上皮中表达,因此开发了一种使用针对GSTπ的亲和纯化多克隆抗体的免疫组织化学检测方法,以研究原发性乳腺癌患者癌细胞中GSTπ表达与激素受体表达以及预后之间的可能关系。
在我们对189例原发性乳腺癌患者的研究中,发现GSTπ表达与ER(双侧P[P2]=0.002)和PR状态(P2=0.023)之间存在强烈的负相关。GSTπ表达与肿瘤大小、淋巴结转移、核分级、组织学或患者年龄无关。在淋巴结阴性乳腺癌(n=72)中,GSTπ表达增加与无病生存期(DFS)和总生存期(OS)降低相关。当将GSTπ表达分为阴性(无GSTπ阳性肿瘤细胞)、中等(1%至70%GSTπ阳性肿瘤细胞)和高(>70%GSTπ阳性肿瘤细胞)类别时,淋巴结阴性乳腺癌患者肿瘤复发的相对风险在每个连续的表达类别中增加3.39倍(P2=0.0045;95%置信区间,1.46至7.87),死亡的相对风险在每个连续类别中增加4.49倍(P2=0.0003;95%置信区间,2.02至10.42)。阴性、中等和高肿瘤组的精算5年OS分别为100%、79%和51%,DFS分别为94%、77%和44%。在多变量分析(ER状态、PR状态、核分级和肿瘤大小)研究的因素中,GSTπ表达是最准确预测淋巴结阴性患者较短DFS和OS的因素。
GSTπ表达与乳腺癌中的激素受体状态呈负相关。这项初步研究还表明,GSTπ表达增加可能是淋巴结阴性乳腺癌患者早期复发和死亡的重要预测指标,值得进一步研究。